Navigation Links
URAC Releases Standards and Measures for Wellness Programs for Public Comment
Date:6/24/2008

nization, is well-known as a leader in promoting health care quality through its accreditation and certification programs. URAC offers a wide range of quality benchmarking programs and services that keep pace with the rapid changes in the health care system, and provide a symbol of excellence for organizations to validate their commitment to quality and accountability. Through its broad-based governance structure and an inclusive standards development process, URAC ensures that all stakeholders are represented in establishing meaningful quality measures for the entire health care industry. For more information, visit http://www.urac.org .

(1) Gurchiek, Kathy. "Wellness Programs Are Growing Global Phenomenon, Report Finds." Society for Human Resource Management. October 17, 2007. http://www.shrm.org/hrnews_published/archives/CMS_023366.asp .


'/>"/>
SOURCE URAC
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine news :

1. HealthGrades releases Fifth Annual Womens Health in American Hospitals study
2. Baxter Releases Ninth Annual Sustainability Report
3. Partnership Releases 20th Annual Survey of Parental Attitudes Toward Drug Use
4. United Cerebral Palsy Releases Annual State Medicaid Rankings
5. Trust for Americas Health Releases Report on Connection between Womens Health and Stalled Infant Mortality Rates
6. Fitness Anywhere, Maker of the TRX Suspension Trainer(TM), Releases Two New Specialized Training Programs
7. Edge Health Solutions Releases edgeDMS(TM) 2.0 and edgeMD 2.0(TM), Revolutionary All-in-One Practice Management Software with FDA-Approved Advanced Visualization
8. The Foundation for Biomedical Research (FBR) Releases Feature DVD Majestic for World Premiere
9. Abbott Releases 2007 Global Citizenship Report Highlighting Strong Commitment to Access to Health Care
10. ACP releases framework for policies enabling access to affordable health insurance coverage
11. Moonview Sanctuary Releases First Case Study of Client Treated Using Unique Moonview Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2008)... WASHINGTON, Dec. 2 EIN...site providing in-depth news on breast cancer. , ...re patients are finding out that information is on... , Responding to the growing demand for accur...ors, screening procedures and drugs to treat it, E...
(Date:12/2/2008)..., A study led by researchers at The University of...e body from lung cancer. , The research, publish...demy of Sciences , USA and funded by a 72,000 gran... the tumour suppressor gene, LIMD1, is responsible...er paving the way for possible new treatments and...
(Date:12/2/2008)..., The Center for the Study of Law, Science, and T...w at Arizona State University will host an interna...iz., on the future of forensic science, with speci...he U.S. National Academy of Sciences, "Identifying..., In addition to experts from universities such a...
(Date:12/2/2008)... LONGMONT, Colo., Dec. 2 MicroPhag...oday that Lynn M. Taussig, MD has joined,the comp...nd CEO of National,Jewish Medical and Research Ce...for studying respiratory diseases, from 1993 to 20...gy. , "I have followed MicroPhage extensive...
Breaking Medicine News(10 mins):Health News:EIN News Introduces 'Breast Cancer News Today'; Website Offers Information on Risk Factors, Treatment, Drugs 2Health News:Gene which protects against lung cancer identified 2Health News:MicroPhage Selects Lynn Taussig, MD for Board of Directors 2
...study has found that smoking may hamper alcoholics... nine months period of alcohol abstinence . Abou... who take alcoholism treatment are chronic smokers... may interfere with the neurocognitive recovery of...
.../actress Mandy Moore admits that she doesn't mind ... The 23-year-old insisted that its part of her job...t is not a 'personal thing'. "It's not a personal...hat I have to do for my job: shape up a little bit...
...nual UN report on illegal drugs has said that opiu...rol . The World Drug Report says over 90 percent ...mes from Afghanistan. According to a BBC report,...um poppies increased dramatically in the country, ...
...people with diabetes can lose weight if they use p...tion sizes, a new study has found. The study was...lgary, Alberta, Canada led by Dr Sue D. Pedersen, ...onducted a six-month controlled trial of commercia...
Other Medicine News:Health News:Smoking Hampers Alcoholics' Neurocognitive Recovery During Abstinence 2Health News:Smoking Hampers Alcoholics' Neurocognitive Recovery During Abstinence 3Health News:Using Portion-control Dishes can Help Obese Diabetics Lose Weight 2
(Date:12/1/2008)... SINGAPORE, Dec. 1 S*BIO Pte Ltd ...ical trial of SB1518, a potent and orally-active J...alia for patients with chronic idiopathic myelofib... evaluate the safety and tolerability of SB1518 in... 50 patients. The Phase 1 part of the study will ...
(Date:12/1/2008)... Baby Girl with Hypophosphatasia Treated With ENB...re in Winnipeg , , MONTREAL, Dec. 1 /PRNews...ch company focused on developing novel therapeutic... the first infant patient in its clinical program ...ating Enzyme Replacement Therapy (ERT) with ENB-00...
(Date:12/1/2008)... , Abstinence is still the best policy , ...ire/ -- A new study from Mayo Clinic finds the use...ating alcoholic hepatitis, an acute inflammation o...ohol. The results of the study are published in th...w.gastrojournal.org/ ). , , VIDEO ALERT: A...
(Date:12/1/2008)... KVISTGARD, Denmark, December 1 /PRNewswire-F...ued in 2007 with the intent to procure an MVA-base...s and Government Services,Canada, on behalf of th...rded,a contract to Bavarian Nordic for the delive...es intend to use IMVAMUNE(R) as part of the,count...
Breaking Medicine Technology:S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3BioVex to Report Phase II Clinical Trial Results of OncoVEX GM CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2100 1BioVex to Report Phase II Clinical Trial Results of OncoVEX GM CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2100 2BioVex to Report Phase II Clinical Trial Results of OncoVEX GM CSF in Metastatic Melanoma at the 2008 American Society of Clinical Oncology Meeting 2100 3Anesiva Announces May 22 2008 Presentation at Citi Investment Research Global HealthCare Conference 19576 1New Gene Methylation Test for Prostate Cancer Available 2096 1Jazz Pharmaceuticals to Present at Investor Conferences 19573 1
...(MARKET WIRE) -- July 02, 2007 -- DOR BioPharma, I...ed today that the,first results from testing of a ...T-VACC™, have been published in the journal,... Infection and,Immunity, v. 75, p. 3043 ). These r...immunity elicited by a multivalent vaccine,that is...
... Update to Timeline for Second Pivotal Phase 3 Tri...Call/ -- Advanced Life,Sciences Holdings, Inc. , t...ficacy data from Trial CL-06, the first of two,piv...e safety and,effectiveness of cethromycin, a novel...nity acquired pneumonia (CAP). The Company,also pr...
Other Medicine Technology:DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC 2DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC 3DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC 4DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC 5DOR BioPharma Announces Publication Describing Results of Its,Multivalent Botulinum Toxin Vaccine BT-VACC 6Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 2Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 3Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 4Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 5Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 6Advanced Life Sciences Announces Supplemental Efficacy Data from,First Pivotal Phase 3 Pneumonia Clinical Trial 7
The Surgiflex WAVE XP couples the state-of-the-art Surgiflex WAVE Probe with the convenience of a truly portable battery-powered pump.
...ARE TVT is a minimally invasive, highly effective ...rinary incontinence. GYNECARE TVT is positioned cl...when needed, TVT provides tension-free support of ... takes approximately 20 to 30 minutes, with minima...
SUR-FIT® AutoLock® Urostomy Pouch with Accuseal® Tap
New Image Urostomy Pouch, Ultra-Clear
Medicine Products: